Agios Pharmaceuticals (AGIO)
(Real Time Quote from BATS)
$40.36 USD
-0.56 (-1.37%)
Updated Oct 14, 2025 03:55 PM ET
After-Market: $40.22 -0.14 (-0.35%) 4:18 PM ET
5-Strong Sell of 5 5
D Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AGIO 40.36 -0.56(-1.37%)
Will AGIO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AGIO
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?
Vertex (VRTX) Down 0.8% Since Last Earnings Report: Can It Rebound?
Other News for AGIO
AGIO's price rises by 0.76% on October 13, though its technical setup remains stable.
AGIO forms Slingshot Bullish on October 10
AGIO forms Upper Bollinger Band Walk on October 9
COMMODORE CAPITAL LP Acquires Significant Stake in SAB Biotherapeutics Inc
AGIO rises 4.23% on October 8, leaving the technical picture intact